Department of Neonatal Medicine, Xin-Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Department of Endocrinology and Genetic Metabolism, Xin-Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Mol Genet Genomic Med. 2019 Jun;7(6):e684. doi: 10.1002/mgg3.684. Epub 2019 Apr 9.
Rare diseases are complex disorders with huge variability in clinical manifestations. Decreasing cost of next-generation sequencing (NGS) tests in recent years made it affordable. We witnessed the diagnostic yield and clinical use of different NGS strategies on a myriad of monogenic disorders in a pediatric setting.
Next-generation sequencing tests are performed for 98 unrelated Chinese patients within their first year of life, who were admitted to Xin Hua Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, during a 2-year period.
Clinical indications for NGS tests included a range of medical concerns. The mean age was 4.4 ± 4.2 months of age for infants undergoing targeting specific (known) disease-causing genes (TRS) analysis, and 4.4 ± 4.3 months of age for whole-exome sequencing (WES) (p > 0.05). A molecular diagnosis is done in 72 infants (73.47%), which finds a relatively high yield with phenotypes of metabolism/homeostasis abnormality (HP: 0001939) (odds ratio, 1.83; 95% CI, 0.56-6.04; p = 0.32) and a significantly low yield with atypical symptoms (without a definite HPO term) (odds ratio, 0.08; 95% CI, 0.01-0.73; p = 0.03). TRS analysis provides molecular yields higher than WES (p = 0.01). Ninety-eight different mutations are discovered in 72 patients. Twenty-seven of them have not been reported previously. Nearly half (43.06%, 31/72) of the patients are found to carry 11 common disorders, mostly being inborn errors of metabolism (IEM) and neurogenetic disorders and all of them are observed through TRS analysis. Eight positive cases are identified through WES, and all of them are sporadic, of highly variable phenotypes and severity. There are 26 patients with negative findings in this study.
This study provides evidence that NGS can yield high success rates in a tertiary pediatric setting, but suggests that the scope of known Mendelian conditions may be considerably broader than currently recognized.
罕见病是临床表现差异巨大的复杂疾病。近年来,下一代测序(NGS)检测成本的降低使其变得负担得起。我们在儿科环境中见证了不同 NGS 策略在无数单基因疾病中的诊断效果和临床应用。
在两年期间,对上海交通大学医学院附属新华医院的 98 名 1 岁以内的非相关中国患者进行了下一代测序测试。
NGS 测试的临床指征包括一系列医疗问题。接受靶向特定(已知)致病基因(TRS)分析的婴儿的平均年龄为 4.4 ± 4.2 个月,而全外显子组测序(WES)的平均年龄为 4.4 ± 4.3 个月(p > 0.05)。72 名婴儿(73.47%)进行了分子诊断,代谢/稳态异常(HP:0001939)表型的检出率相对较高(优势比,1.83;95%置信区间,0.56-6.04;p = 0.32),而无明确 HPO 术语的非典型症状的检出率明显较低(优势比,0.08;95%置信区间,0.01-0.73;p = 0.03)。TRS 分析的分子检出率高于 WES(p = 0.01)。在 72 名患者中发现了 98 种不同的突变,其中 27 种以前没有报道过。将近一半(43.06%,31/72)的患者携带 11 种常见疾病,主要是先天性代谢缺陷(IEM)和神经遗传疾病,均通过 TRS 分析发现。通过 WES 发现了 8 个阳性病例,均为散发性、表型和严重程度变化较大的病例。本研究有 26 名患者检测结果为阴性。
本研究表明 NGS 在三级儿科环境中具有较高的成功率,但提示已知孟德尔疾病的范围可能比目前认识的要广泛得多。